Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

British science needs help to eradicate malaria

The response to Covid-19 has been a high-profile demonstration of Britain using its status as a science superpower for good. The Oxford/AstraZeneca vaccine has been distributed in billions of doses around the world, saving huge numbers of lives and helping to pave the way out of this pandemic. Now, another innovation from the Jenner Institute, University of Oxford, has the potential to save more lives: a new vaccine to tackle malaria, a disease that kills a child nearly every minute. (Paywall)

Oxford Covid Jab Team ends century long malaria mystery

One of humanity’s most deadly and enduring public health challenges appears to have been cracked by scientists behind the Oxford coronavirus jab. A century after research into the disease first began, trials have shown a vaccine produced by the Jenner Institute to be the most effective weapon ever developed against malaria. The disease kills a young child every minute, most of them in Africa. (Paywall)

Blueprint for new adenovirus-based vaccines within 100 days

Jenner researchers have published a pre-print on how new adenovirus-based vaccines could be produced at large-scale within 100 days of identification of a new virus or variant. They also report an improved manufacturing method which could enable production of 1 billion doses per month. The paper is being submitted to BioRxiv and a peer-reviewed journal, and is temporarily available here:

£50m funding for Poonawalla Vaccines Research Building at Oxford University

The Poonawalla Vaccines Research Building is to be established at Oxford University's Old Road Campus following a £50m funding commitment from Serum Life Sciences, a subsidiary of Serum Institute of India. The building will be a new home for the Jenner Institute. The donation will be the University’s largest ever gift for vaccines research.

One week left to apply for Vaccinology Training

In this open call TRANSVAC2 offers free advanced courses on Adjuvants and Vaccine Formulations, Statistics of vaccine evaluation, and Regulatory aspects of vaccine development. Apply until December 15th at www.transvac.org.

Professor Dame Sarah Gilbert delivers BBC Dimbleby Lecture

Featuring notable speakers from business, science or politics since 1972, Prof. Gilbert delivered the 44th Richard Dimbleby Lecture, held this year at Oxford's Blavatnik School of Government. Dame Sarah Gilbert is the Saïd Professor of Vaccinology, at the Jenner Institute & Nuffield Department of Clinical Medicine. The lecture is available (in the UK) via the BBC iPlayer.

Phase I HIV vaccine trial completes volunteer recruitment in time for World AIDS Day

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) is pleased to announce the completion of recruitment of volunteers for the Phase I HIV-CORE 006 HIV vaccine clinical trial at four sites in Kenya, Uganda and Zambia. Enrolment of the final participants took place today at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, on World AIDS Day.

Fighting diseases with cross-species vaccination

The 2021 Royal Society Africa Prize Seminar will be given by Professor George Warimwe, Jenner Investigator. More than 70% of these infectious diseases are zoonotic, with some causing illness and death in humans as well as the animal host. Professor Warimwe will discuss his ‘one health' approach to developing a single Rift Valley Fever vaccine suitable for humans and livestock. The lecture will take place online 2 December at 6.30pm GMT.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Oxford vaccine reaches two billion dose milestone

University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines.

$2m fund awarded for Oxford’s single-cell ancestry vaccine research

The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells. The Oxford team includes a number of investigators across several departments including the Jenner Institute. Find out more: (https://www.ox.ac.uk/news/2021-11-16-2m-fund-awarded-oxford-s-single-cell-ancestry-vaccine-research)

Ebola vaccine to begin human trials

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.

£200,000 funding boost for Oxford’s Clinical BioManufacturing Facility

The Oxfordshire Local Enterprise Partnership (OxLEP) has secured funding to support the University of Oxford’s Clinical BioManufacturing Facility (CBF) – a UK leader in the production of vaccines for early phase clinical trials, including the Oxford-AstraZeneca vaccine.

Vaccine for treating cancer made possible using Oxford COVID vaccine technology

Research from Jenner Institute and Ludwig Institute for Cancer Research has shown the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. When tested in mice, the cancer vaccine increased levels of anti-tumour T cells infiltrating tumours and improved efficacy of cancer immunotherapy. Compared to immunotherapy alone, the combination with the vaccine showed a greater reduction in tumour size and improved survival of the mice.

Royal Society Africa Prize winner 2021

The Royal Society Africa Prize 2021 is awarded to Professor George Warimwe, Jenner Investigator, for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. Professor Warimwe will be awarded a medal and a grant of £15,000 towards his research project at a symposium to be held at a future date.

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network, co-directed by Jenner Investigator Prof Helen McShane, has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation. An effective vaccine for TB is one of the primary goals of the VALIDATE Network which aims to accelerate vaccine development for complex intracellular pathogens that are often neglected.

Making a billion doses of vaccine in 18 months: starting with two tablespoons

As the University was planning the first clinical trials for the COVID-19 vaccine, some began to wonder how to supply the vaccine to the world - if it worked. Although Oxford had the capacity to develop a COVID-19 vaccine, and clinical trials might take only a few months, manufacturing ‘at pandemic scale’ would take much longer. A group of University scientists had, however, worked on the problem for some time.

Applications now open for Vaccinology in Africa Course 2021

The course provides teaching in human and veterinary vaccinology by an exceptional faculty of academic and industrial speakers, with an emphasis on strengthening vaccine development and manufacturing autonomy in Africa. The course alternates between East and West Africa. In 2021, participation is for attendees working or studying in East Africa. Applications close 31 August.

African trial of novel HIV vaccine candidate starts

Professor Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute, and lead researcher on the trial, said: ‘This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.’

Load More